Medicinal Codeine Exemption: Qualifying cough syrup remains outside NDPS controls unless knowingly diverted for intoxication or non-medicinal trafficking.
Qualifying codeine cough syrup remains outside the NDPS Act when it meets the Entry 35 composition limits, has an established therapeutic character, and is genuinely dealt with by a licensed entity for medicinal or scientific purposes. A Drugs and Cosmetics regulatory breach, including retail sale without prescription, does not alone establish NDPS liability without material showing knowing diversion. The exemption is unavailable where stock, sales or transport are knowingly directed to intoxication or other non-medicinal use; in that event, the entire syrup mixture determines the relevant quantity. Bail depends on individual prima facie evidence of conscious possession, knowledge, diversion, or participation in trafficking, rather than unsupported confessions or weak circumstantial material.
Issues: (i) Whether codeine-based cough syrup within the quantitative limits in Entry 35 of the notification dated 14.11.1985 attracts the NDPS Act when dealt with by a drug licence holder for medicinal use; (ii) Whether such cough syrup attracts the NDPS Act when stocked, sold or transported for intoxication or another non-medicinal purpose; (iii) Whether the respective applicants were entitled to bail on the material attributed to them.
Issue (i): Whether codeine-based cough syrup within the quantitative limits in Entry 35 of the notification dated 14.11.1985 attracts the NDPS Act when dealt with by a drug licence holder for medicinal use.
Analysis: Codeine is an opium derivative and ordinarily a manufactured drug, but Entry 35 excludes a preparation compounded with other ingredients, containing no more than 100 mg per dosage unit and no more than 2.5% concentration, which has been established in therapeutic practice. The expression concerns the established therapeutic character of the preparation, not the end-user's individual use. A codeine cough syrup satisfying these conditions and dealt with in the ordinary medicinal trade by a valid licence holder is outside the category of manufactured drug. A routine retail sale without a prescription may breach the Drugs and Cosmetics regulatory regime, but does not by itself invoke the NDPS Act absent material indicating knowledge of diversion to non-medicinal use.
Conclusion: A qualifying codeine-based cough syrup sold, stocked or transported by a licence holder for medicinal use is not a narcotic substance under the NDPS Act.
Issue (ii): Whether such cough syrup attracts the NDPS Act when stocked, sold or transported for intoxication or another non-medicinal purpose.
Analysis: The statutory exception is available only where the preparation is genuinely dealt with for medical or scientific purposes and consistently with the applicable licensing requirements. The NDPS Act operates in addition to the Drugs and Cosmetics Act; a licence does not protect dealings involving deliberate diversion of a codeine preparation for intoxication. Large-scale diversion, fictitious documentation or entities, absence of actual delivery or stock, forged transport records, and other material indicating non-medicinal trafficking may establish that the exemption is unavailable. Where the NDPS Act applies, the weight of the entire syrup mixture is considered in determining small or commercial quantity.
Conclusion: A qualifying codeine cough syrup knowingly stored, sold or transported for intoxication or another non-medicinal purpose is treated as a codeine preparation and manufactured drug attracting the NDPS Act.
Issue (iii): Whether the respective applicants were entitled to bail on the material attributed to them.
Analysis: Bail was assessed individually without deciding guilt. Bail was justified where the material did not prima facie establish conscious possession, knowledge of concealed contents, actual involvement in diversion, or participation in a trafficking conspiracy beyond unsupported confessional statements or weak circumstantial material. Bail was refused where the record prima facie disclosed organised diversion of very large quantities through fictitious firms, false invoices or transport records, unexplained financial routing, forged documentation, or other evidence of intended non-medicinal distribution.
Conclusion: Bail was granted to applicants against whom prima facie material of conscious involvement in non-medicinal trafficking was insufficient, and refused to applicants against whom such material was prima facie established.
Final Conclusion: The statutory exemption protects genuine medicinal dealings in qualifying codeine cough syrup, but cannot be used to shield its knowing diversion for intoxication; the individual applications were resolved according to the strength of the respective prima facie material.
Ratio Decidendi: A codeine preparation within Entry 35 remains outside the NDPS Act only while it is genuinely dealt with for medical or scientific purposes in accordance with the governing regulatory requirements; knowing diversion for intoxication defeats the exemption.